Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Christian M, Kurbacher"'
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 54, Iss , Pp 88-95 (2020)
Purpose: Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of th
Externí odkaz:
https://doaj.org/article/06b4953fd7094428a800955c7f592096
Autor:
Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. Howe
Externí odkaz:
https://doaj.org/article/3595f6bd2f1948ae89b5ca12ff495d0f
Autor:
Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss
Publikováno v:
Senologie - Zeitschrift für Mammadiagnostik und -therapie. 20:43-56
Zusammenfassung Hintergrund Umfangreiche Daten aus prospektiven klinischen Studien liefern einen hohen Evidenzgrad für den Einsatz von CDK4/6-Hemmern in Kombination mit einer endokrinen Therapie (CDK4/6i + ET) als Standard bei der First-Line-Behandl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e74ba3c06bc446cf560ab25f46195a
https://doi.org/10.1055/a-2008-6553
https://doi.org/10.1055/a-2008-6553
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 55, Iss , Pp 138-139 (2021)
Externí odkaz:
https://doaj.org/article/3ce18d162da74f4b92ea7082883a3131
Autor:
Tobias, Engler, Peter A, Fasching, Diana, Lüftner, Andreas D, Hartkopf, Volkmar, Müller, Hans-Christian, Kolberg, Peyman, Hadji, Hans, Tesch, Lothar, Häberle, Johannes, Ettl, Markus, Wallwiener, Matthias W, Beckmann, Alexander, Hein, Erik, Belleville, Sabrina, Uhrig, Pauline, Wimberger, Carsten, Hielscher, Christian M, Kurbacher, Rachel, Wuerstlein, Michael, Untch, Florin-Andrei, Taran, Hans-Martin, Enzinger, Petra, Krabisch, Manfred, Welslau, Michael, Maasberg, Dirk, Hempel, Michael P, Lux, Laura L, Michel, Wolfgang, Janni, Diethelm, Wallwiener, Sara Y, Brucker, Tanja N, Fehm, Andreas, Schneeweiss
Publikováno v:
Geburtshilfe und Frauenheilkunde. 82:1055-1067
Background Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as a standard for the treatment of HER2-negative, hormone recept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b025963af12454faef60ebf08259e4
https://doi.org/10.1055/a-1880-0087
https://doi.org/10.1055/a-1880-0087
Autor:
Peyman Hadji, Oliver Stoetzer, Thomas Decker, Christian M. Kurbacher, Frederik Marmé, Andreas Schneeweiss, Christoph Mundhenke, Andrea Distelrath, Peter A. Fasching, Michael P. Lux, Diana Lüftner, Wolfgang Janni, Mathias Muth, Julia Kreuzeder, Claudia Quiering, Eva-Marie Grischke, Hans Tesch
Publikováno v:
Journal of Bone Oncology, Vol 14, Iss , Pp - (2019)
Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase
Externí odkaz:
https://doaj.org/article/c2654a29bfbd4af0b90b6c2e4cd0ef03
Autor:
Matthias W. Beckmann, Lothar Häberle, Christoph Thomssen, Michael P. Lux, Rachel Wuerstlein, Michael Untch, Friedrich Overkamp, Peyman Hadji, Tanja Fehm, Bernhard Volz, Erik Belleville, Alexander Hein, Wolfgang Janni, Hans Tesch, Andreas Schneeweiss, Lena A. Wurmthaler, Christian M. Kurbacher, Johannes Ettl, Carsten Hielscher, Florin-Andrei Taran, Volkmar Müller, Andreas D. Hartkopf, P Wimberger, Sara Y. Brucker, Hans-Christian Kolberg, Diana Lüftner, Diethelm Wallwiener, Peter A. Fasching, Julius Emons, Markus Wallwiener
Publikováno v:
European Journal of Cancer. 155:1-12
Purpose Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff9454fc61f6be3b80d26db44b681593
https://doi.org/10.1016/j.ejca.2021.06.033
https://doi.org/10.1016/j.ejca.2021.06.033
Autor:
Radoslav Chekerov, Mustafa Deryal, Bahriye Aktas, Robert Röhle, Annika Stürzebecher, Marco J Battista, Christian M Kurbacher, Pauline Wimberger, Ralf Lorenz, Jana Barinoff, Gunther Rogmans, Jens Kosse, Maximilian Klar, Tomas Kupec, Bernd Christensen, Gülten Oskay-Özcelik, Thomas Illmer, Thorsten Götze, Klaus Pietzner, Jalid Sehouli
Publikováno v:
Ovarian cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fac97ed64f9db6709896b13ef07bb56e
https://doi.org/10.1136/ijgc-2022-esgo.541
https://doi.org/10.1136/ijgc-2022-esgo.541
Autor:
Steffi Busch, Claus Hanusch, Christian M. Kurbacher, Jörg Schilling, Janine Kreiss-Sender, Elisa Flahaut, Daniela Rezek, Martin Holländer, Meinolf Karthaus
Publikováno v:
Breast Care (Basel)
Introduction: In a prospective non-interventional study involving 2,173 patients, we showed that use of the oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg (NEPA) for prevention of chemotherapy (Ctx)-induced nausea and vomiting ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2743479252f515ed427ceab194b315c
https://doi.org/10.1159/000514891
https://doi.org/10.1159/000514891
Autor:
Wolfgang Janni, Hans Tesch, Mattea Reinisch, J Schubert, Christian M. Kurbacher, Andreas D. Hartkopf, Martin Schuler, Tanja Fehm, Arndt Nusch, Diana Lüftner, Petra Krabisch, Thomas Decker, Roswitha Fuchs, Sara Y. Brucker, Peter A. Fasching, Andreas Schneeweiss, Claudia Voges, Bernhard Heinrich, Sherko Kuemmel
Publikováno v:
Cancer Research. 81:PS10-31
Introduction: RIBECCA is a national, multi-center, open-label, single-arm phase IIIb trial assessing the efficacy and safety of ribociclib in combination with letrozole in a patient population similar to the populations of MONALEESA-2, -3 and -7, inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::448324268a9820bbb088bf6a97bea395
https://doi.org/10.1158/1538-7445.sabcs20-ps10-31
https://doi.org/10.1158/1538-7445.sabcs20-ps10-31